AVITA Medical (ASX:AV) secures FDA approval

Company News

by Katrina Bullock

Dual listed, medical tech company, AVITA Medical (ASX:AVH, NASDAQ:RECEL) has announced the resignation of joint company secretary Tamara Barr.

Her tenure in the role was short lived, following her appointment in only September of this year. Mark Licciardo, also of Mertons, will continue to act as Company Secretary of Avita Medical.

This news comes as the company receives US FDA approval to conduct a feasibility study evaluating the safety and effectiveness of the RECELL® Autologous Cell Harvesting Device for repigmentation of lesions.

The device is designed to assist Vitiligo, a skin condition which affects approximately 6.5 million people in the United States.

Shares in AVITA Medical (ASX:AVH) closed 2.4 per cent higher at 64 cents on Friday.
 

Katrina Bullock

Finance News Network
Katrina is a respected TV journalist, as well as a renowned presenter and award winning lawyer. She holds a Bachelor of Laws (Honours 1st class, division 1), a Bachelor of Business (with Distinction) and is currently undertaking a PhD in Law focused on stock exchange disclosures and corporate governance. She began her career as a corporate lawyer in an Australian top tier commercial law firm and is currently the General Counsel of Greenpeace Australia Pacific. In 2020 Katrina was named one of the 30 best lawyers in Australia under 30 by Lawyer's Weekly.